Crucible Therapeutics and SITraN secure £2.3 million Innovate UK Biomedical Catalyst award to develop breakthrough siRNA therapies that address underlying causes of ALS
Crucible Therapeutics, a biotechnology company developing novel gene therapies for neurodegenerative diseases, is pleased to announce that it has been awarded a substantial £2.3M grant from Innovate UK’s Biomedical Catalyst program …
University of Sheffield spinout company Crucible Therapeutics raises £5 million to advance pioneering treatments for neurological diseases
University of Sheffield spinout company, Crucible Therapeutics, a biotechnology company developing novel therapies to treat amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD), has secured £5 million financing from Northern Gritstone and Argobio Studio.
